Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 477 across all filing types
Latest filing 2023-05-26 Regulatory Filings
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Dividend
Regulatory Filings
2023-05-26 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure under regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It announces the execution of a long-term supply and sales agreement with a European company. The content is an update on a business agreement and does not contain financial statements, audit information, or detailed financial results. It is a regulatory announcement about a material event affecting the company. The document length is short (2238 characters) and it is an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-05-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification dated May 20, 2023, informing about an upcoming earnings call scheduled for May 29, 2023, to discuss the operational and financial performance for the fourth quarter and fiscal year ended March 31, 2023. It includes details such as the date, time, participants, and dial-in numbers for the call. The document does not contain any actual financial data or results but serves as an announcement of the earnings call event. According to the classification rules, announcements of earnings calls are classified as Call Transcript (CT) only if they contain the full transcript. Since this document is only an intimation or invitation to the earnings call, it does not qualify as a transcript or an earnings release. It is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement informing the market about the earnings call, without substantive financial data or the transcript itself.
2023-05-20 English
Board Meeting — SUPRIYA LIFESCIENCE LIMITED has informed the Exchange about Board Meeting to be held on 26-May-2023 to consider and approve the Yearly Audited Financial results of the Company for the…
Regulatory Filings
2023-05-19 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a letter dated May 19, 2023, addressed to stock exchanges (BSE and NSE) informing about an upcoming Board Meeting scheduled for May 26, 2023. The purpose of the meeting is to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2023, and to recommend dividends if any. The letter also mentions the closure of the trading window in compliance with insider trading regulations. The document does not contain the financial results themselves but is an announcement of the Board Meeting where such results will be approved. The document length is 2581 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement informing about a board meeting and upcoming financial results, not the financial report itself or a detailed management discussion.
2023-05-19 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2023-05-18 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.